Wells Fargo Boosts Septerna Rating to Overweight and Increases Price Target to $28
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 14 2025
0mins
Source: Benzinga
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies.
Market Intelligence: Benzinga Pro is positioned as a source for the most accurate and timely stock market intelligence available.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on SEPN
Wall Street analysts forecast SEPN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SEPN is 33.14 USD with a low forecast of 25.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 23.800
Low
25.00
Averages
33.14
High
43.00
Current: 23.800
Low
25.00
Averages
33.14
High
43.00
About SEPN
Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. It is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aktis Oncology Launches $200 Million IPO with $100 Million Investment from Eli Lilly
- IPO Market Recovery: Aktis Oncology launched a $200 million IPO on Monday, indicating a resurgence in the biotech IPO market after a period of uneven performance, and is set to be the first significant IPO of 2026.
- Increased Financing Size: Just two days after the IPO launch, Aktis upsized the deal by 50%, which not only reflects growing investor confidence in its prospects but also indicates a rising interest in the biotech sector.
- Strategic Partnership Support: Aktis disclosed a $100 million investment from partner Eli Lilly, which will provide robust support for the company's R&D and market expansion, further strengthening its position in the competitive biotech landscape.
- Optimistic Market Outlook: As the first major biotech IPO of 2026, Aktis's success could attract more investor attention to the biotech sector, potentially driving recovery and growth across the industry.
Continue Reading
Septerna Appoints Mark A. Wilson as Chief Legal Officer to Enhance Governance
- Executive Appointment: Septerna has appointed Mark A. Wilson as Chief Legal Officer, leveraging his over 25 years of experience in intellectual property and corporate law to enhance the company's governance framework and maximize the value of its proprietary Native Complex Platform™.
- Strategic Importance: Wilson's previous role at Nektar Therapeutics, where he led global development and commercialization collaborations, equips him to effectively execute Septerna's long-term drug development strategy.
- Industry Context: As a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, Wilson's expertise will further drive innovation and development in this critical area.
- Talent Acquisition: With a Bachelor of Science in Pharmacy and a Juris Doctor degree, and being registered with the U.S. Patent and Trademark Office, Wilson's addition will enhance Septerna's legal and intellectual property management capabilities.
Continue Reading